Breast Cancer Data

Market Dynamics and Outcomes

The breast cancer market involves the greatest number of annual diagnoses per year at over 284,000 cases, with relatively high rates of survival depending upon stage of disease.  This segment is one of the more clearly defined in the oncology space in terms of clinical treatment pathways with effective therapies depending on hormone status and genetic tumor markers.  At the time of diagnosis, approximately 64% of breast cancers are localized, 27% are regional and 6% are distant (metastatic).  One of the most competitive classes of drugs is the CDK 4/6 group which treats advanced HR+,HER2- tumors is now moving into the adjuvant setting.  Keytruda has been recently approved for PD-L1 triple negative breast cancer (TNBC).